Instead of looking outside of the body, we believe the smart way of looking for new medicines is by learning from the body and from molecules that exist in the body. Just like the body’s bacterial microbiome, viruses are a source of immune modifying proteins and peptides. Therefore, our peptide technology is derived from what we call the body’s “Virobiome”.
As these immune modifying peptides evolved to function within the intact host immune system, they are both highly potent and have a nuanced receptor bias that modulates multiple biological effects that would be difficult, if not impossible, to design or discover by typical drug screening methods. The peptides we create have the highly desired pharmacologic property of being partial antagonists, as they balance excess immune responses without completely shutting them down, while activating repair processes.
We call our peptides Receptides to indicate their receptor mediated actions that modulate a cluster of innate immune chemokine receptors (CCR2/5/8,CXCR4). Chemokine receptors act on both immune cells and neurons to sculpt neuronal connections and synapses. Blocking these receptors has been shown to inhibit the neurotoxic effects of microglial and astrocyte activation which then restores synapses and dendritic arbor to stop, even reverse, the neuronal damage that underlies chronic pain, dementia’s, stroke and brain injury, and now even opioid use disorders.